M Indrová

1.0k total citations
75 papers, 840 citations indexed

About

M Indrová is a scholar working on Immunology, Molecular Biology and Oncology. According to data from OpenAlex, M Indrová has authored 75 papers receiving a total of 840 indexed citations (citations by other indexed papers that have themselves been cited), including 61 papers in Immunology, 27 papers in Molecular Biology and 21 papers in Oncology. Recurrent topics in M Indrová's work include Immunotherapy and Immune Responses (53 papers), Immune Cell Function and Interaction (22 papers) and Virus-based gene therapy research (16 papers). M Indrová is often cited by papers focused on Immunotherapy and Immune Responses (53 papers), Immune Cell Function and Interaction (22 papers) and Virus-based gene therapy research (16 papers). M Indrová collaborates with scholars based in Czechia, Denmark and Russia. M Indrová's co-authors include J Bubeník, Jana Šímová, Jana Bieblová, Milan Reiniš, Romana Mikyšková, T Jandlová, Elżbieta Pajtasz‐Piasecka, Ivan Štěpánek, V. Vonka and Peter Perlmann and has published in prestigious journals such as British Journal of Cancer, International Journal of Cancer and Journal of Leukocyte Biology.

In The Last Decade

M Indrová

73 papers receiving 825 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
M Indrová Czechia 16 588 292 281 127 103 75 840
Jana Šímová Czechia 15 533 0.9× 269 0.9× 231 0.8× 109 0.9× 108 1.0× 63 723
Ronald Rooke France 14 462 0.8× 175 0.6× 191 0.7× 103 0.8× 69 0.7× 31 924
T Hamaoka Japan 10 755 1.3× 411 1.4× 171 0.6× 44 0.3× 78 0.8× 11 901
Anatoli Malyguine United States 20 785 1.3× 455 1.6× 268 1.0× 85 0.7× 116 1.1× 36 1.2k
Ingo Fricke United States 10 906 1.5× 639 2.2× 331 1.2× 96 0.8× 83 0.8× 16 1.3k
Ferdynand Kos United States 12 501 0.9× 241 0.8× 158 0.6× 227 1.8× 34 0.3× 15 725
Jean‐Paul Rivals Switzerland 12 774 1.3× 461 1.6× 186 0.7× 81 0.6× 64 0.6× 16 1.1k
R. Ian Cumming United States 9 635 1.1× 298 1.0× 495 1.8× 41 0.3× 101 1.0× 13 955
Sinéad M. Lougheed Netherlands 22 1.0k 1.7× 644 2.2× 342 1.2× 79 0.6× 98 1.0× 37 1.3k
R Brew United Kingdom 10 303 0.5× 224 0.8× 155 0.6× 35 0.3× 123 1.2× 16 579

Countries citing papers authored by M Indrová

Since Specialization
Citations

This map shows the geographic impact of M Indrová's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M Indrová with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M Indrová more than expected).

Fields of papers citing papers by M Indrová

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M Indrová. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M Indrová. The network helps show where M Indrová may publish in the future.

Co-authorship network of co-authors of M Indrová

This figure shows the co-authorship network connecting the top 25 collaborators of M Indrová. A scholar is included among the top collaborators of M Indrová based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M Indrová. M Indrová is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
3.
Rosalia, Rodney Alexander, Ivan Štěpánek, Jana Šímová, et al.. (2012). Administration of anti-CD25 mAb leads to impaired α-galactosylceramide-mediated induction of IFN-γ production in a murine model. Immunobiology. 218(6). 851–859. 7 indexed citations
4.
Šímová, Jana, M Indrová, Romana Mikyšková, et al.. (2011). Immunotherapy augments the effect of 5-azacytidine on HPV16-associated tumours with different MHC class I-expression status. British Journal of Cancer. 105(10). 1533–1541. 35 indexed citations
5.
Šímová, Jana, et al.. (2009). Therapy for minimal residual tumor disease: β‐Galactosylceramide inhibits the growth of recurrent HPV16‐associated neoplasms after surgery and chemotherapy. International Journal of Cancer. 126(12). 2997–3004. 9 indexed citations
6.
7.
Šímová, Jana, et al.. (2005). Immunotherapeutic Efficacy of Vaccines Generated by Fusion of Dendritic Cells and HPV16-Associated Tumour Cells. Folia Biologica. 51(1). 19–24. 6 indexed citations
8.
Pajtasz‐Piasecka, Elżbieta, Joanna Rossowska, Agnieszka Krawczenko, et al.. (2004). Loss of Tumorigenicity of Murine Colon Carcinoma MC38/0 Cell Line after Transduction with a Retroviral Vector Carrying Murine IL-12 Genes. Folia Biologica. 50(1). 7–14. 30 indexed citations
9.
Indrová, M, Milan Reiniš, J Bubeník, et al.. (2004). Immunogenicity of Dendritic Cell-Based HPV16 E6/E7 Peptide Vaccines: CTL Activation and Protective Effects. Folia Biologica. 50(6). 184–193. 14 indexed citations
10.
11.
Mendoza, Luis, J Bubeník, Jana Šímová, et al.. (2002). Tumour-Inhibitory Effects of Dendritic Cells Administered at the Site of HPV 16-Induced Neoplasms. Folia Biologica. 48(3). 114–119. 7 indexed citations
12.
Mendoza, Luis, J Bubeník, M Indrová, et al.. (2002). Freezing and Thawing of Murine Bone Marrow-Derived Dendritic Cells Does Not Alter Their Immunophenotype and Antigen Presentation Characteristics. Folia Biologica. 48(6). 242–245. 6 indexed citations
13.
Indrová, M, Luis Mendoza, Milan Reiniš, et al.. (2001). Bone marrow dendritic cell-based anticancer vaccines. Advances in experimental medicine and biology. 495. 355–358. 2 indexed citations
14.
Mendoza, Luis, M Indrová, Milan Reiniš, et al.. (2000). Peritumoral Administration of Antigen-Unstimulated Bone Marrow-Derived Dendritic Cells Inhibits Tumour Growth. Folia Biologica. 46(3). 91–97. 15 indexed citations
15.
Indrová, M, et al.. (1999). Interleukin 2 gene therapy of surgical minimal residual tumour disease: characterization of cytolytic effector cells from tumour progressors and regressors.. PubMed. 45(6). 227–31. 4 indexed citations
16.
Bubeník, J, et al.. (1997). Tumour vaccines expressing IL-2, CD80, and IL-2 plus CD80 gene. International Journal of Oncology. 11(6). 1213–9. 3 indexed citations
17.
Indrová, M, et al.. (1996). Cross-reactivity of murine and hamster IL-2 mitogenic signal. Immunology Letters. 50(1-2). 115–117. 1 indexed citations
18.
Šímová, Jana, et al.. (1995). Interleukin-2 gene therapy of residual EL-4 leukaemia potentiates the effect of cyclophosphamide pretreatment. Journal of Cancer Research and Clinical Oncology. 121(1). 39–43. 7 indexed citations
19.
Bubeník, J, et al.. (1987). Lymphokine-activated killer (LAK) cells: I. Age-dependent decline of LAK cell-mediated cytotoxicity. Immunology Letters. 16(2). 113–119. 12 indexed citations
20.
Bubeník, J & M Indrová. (1987). Cancer immunotherapy using local interleukin 2 administration. Immunology Letters. 16(3-4). 305–309. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jana Šímová Breakdown of academic impact, for papers by Ronald Rooke Breakdown of academic impact, for papers by T Hamaoka Breakdown of academic impact, for papers by Anatoli Malyguine Breakdown of academic impact, for papers by Ingo Fricke Breakdown of academic impact, for papers by Ferdynand Kos Breakdown of academic impact, for papers by Jean‐Paul Rivals Breakdown of academic impact, for papers by R. Ian Cumming Breakdown of academic impact, for papers by Sinéad M. Lougheed Breakdown of academic impact, for papers by R Brew
Rankless by CCL
2026